The study looked at real-world prescribing trends for disease-modifying treatments (DMTs) for multiple sclerosis from 2001 to 2020. Over 153,000 DMT-initiating events in adults and 500 occurrences in youngsters were studied. The researchers discovered that adult injectable DMT use decreased by 73.8% throughout the study period, driven by a 61.2% decrease in interferon beta prescriptions. Oral DMT use rose following their debut in 2010, going from 1.1% that year to 62.3% by 2020. Infusion therapy initiations have remained low at roughly 3.2% since 2004, but they have grown somewhat following the launch of ocrelizumab in 2017. Patterns for children were similar, with the exception of a preference for oral medicines over injectable medications. Dimethyl fumarate was the most widely used DMT initiator in adults.

To know more: About the original article click here.